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ABSTRACT
Introduction: OnabotulinumtoxinA (ONA;
Botox, Allergan, Irvine, CA) was discovered
for cosmetic use in the mid-1980s for which
it was FDA approved in April 2002.
AbobotulinumtoxinA (ABO; Dysport, Valeant
Pharmaceuticals International, Inc, Montreal,
Quebec) was FDA approved in April 2009 for
therapeutic and esthetic uses. The most recent
studies make a comparison between the two
formulations; however, information is still
lacking in comparison studies. In this study,
we compare efficacy and safety of a single
treatment of two preparations of botulinum
toxin A in patients with moderate to severe
rhytids in the glabellar and crow’s feet areas.
Methods: A total of 85 patients with moderate
to severe wrinkles in either the glabellar or
crow’s feet area, or both, were given a single
injection on day 0, with ABO and ONA injected
on opposite sides of the face. Follow-up
assessments were done at 2 weeks, 1 month,
3 months, 4 months, and 5 months. The study
end points were onset of action, change in
degree of wrinkles, patient satisfaction,
duration of effect, and adverse effects.
Results: Results of onset of improvement with
ABO vs. ONA in the glabellar and crow’s feet
regions show higher percentage of patients with
earlier onset improvement with ABO. Evaluator
assessment showed ABO lasted longer after
3 months in a significant number of patients
in both areas, 83% with ABO vs. 48% with ONA
at 4 months in the glabellar area, and 65% with
ABO vs. 47% with ONA at 4 months in the
crow’s feet area.
Conclusion: Time to improvement showed
earlier onset and longer duration of
improvement in a higher percentage of
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individuals with ABO when compared with
ONA. ABO provides a safe and effective
alternative in a dose ratio of 2.5:1 and 3:1 in
the glabellar and crow’s feet area, respectively.
Keywords: Botox; Botulinum toxin; Crow’s
feet; Dermatology; Dysport; Facial rhytids;
Glabella
INTRODUCTION
OnabotulinumtoxinA (ONA) has been used since
the early 1980s for reducing muscle spasms in
medical illnesses [1]. Over the past 20 years, ONA
has been recognized by regulatory authorities in
approximately 80 countries worldwide as an
effective treatment for 21 different medical uses
including strabismus, blepharospasm, cervical
dystonia, and severe primary axillary
hyperhidrosis. Its use as a cosmetic agent was
recognized in the mid-1980s and after a decade of
‘off-label’ use, efficacy and tolerability in the
treatment of glabellar frown lines was
demonstrated in two large, multicenter,
randomized, double-blind placebo-controlled
trials, known as Glabellar Lines I and II studies
[1]. These trials led to FDA approval, in April
2002, of ONA for the temporary reduction of
moderate to severe glabellar lines due to
muscular hypertrophy at a dose of 20 units
(U) for adults aged B65 years [2].
AbobotulinumtoxinA (ABO), another
formulation of botulinum toxin A, has been
used worldwide since 1990 and is approved in
76 countries for therapeutic use. It was first
approved for esthetic use outside the United
States in 2001 and is currently marketed in 27
countries for esthetic use before being studied
for use in glabellar lines in the US. After a series
of trials, ABO was approved for the treatment of
glabellar lines by the FDA in April of 2009 [3].
The derivation of ONA and ABO from
botulinum toxin A is responsible for similar
effects on the musculature. Both agents act by
inhibiting the calcium-mediated release of
acetylcholine from the nerve ending, causing
temporary muscle paralysis. The weight of the
core neurotoxin is the same at 150 kDa with
both agents; however, they differ in molecular
weight of the botulinum toxin/hemagglutinin
complex. ONA is a 925-kDa protein and ABO
has been reported as a 400–600 kDa protein, but
the specific weight has not been disclosed by
the manufacturer (Ipsen Ltd, United Kingdom)
[4, 5]. Differences in the molecular weight of the
protein complex have been reported to
theoretically cause ABO to migrate more than
ONA, with a possibility that there would be a
greater incidence of eyelid/eyebrow ptosis with
ABO when injected supraorbitally in the
corrugators, though this effect has not been
reported in the trials [6].
Slight differences in the properties of ABO
and ONA may result in differences in efficacy. It
is the opinion of many physicians, along with
feedback from their patients, that ABO has a
slightly greater efficacy (earlier onset and longer
duration of effect) than ONA, though this
information is largely anecdotal [7]. There
have been several reports on the efficacy and
safety of ONA and ABO, yet the literature
contains few studies comparing these two
drugs [7–12]. Additionally, comparative studies
are lacking evaluating treatment in facial
wrinkles other than in the frown region. A
difference in efficacies might suggest that one
agent is a more suitable option for patients and
clinicians seeking to prolong treatment
intervals yet maintain a continuous effect of
reduced wrinkle appearance.
In this prospective clinical study, we report
the results of a comparison of efficacy
parameters, particularly onset and duration,
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and the safety of ONA and ABO in the
treatment of rhytids in the glabellar and
crow’s feet areas.
METHODS
This was a prospective, comparative, triple-
blinded, single-center, randomized, internally
controlled clinical trial.
Subject Population
A four-point grading scale was used to evaluate
wrinkle severity at maximum contraction in the
glabellar and crow’s feet areas: 0 = no wrinkles,
1 = mild wrinkles, 2 = moderate wrinkles,
3 = severe wrinkles [13–15] (Fig. 1). Only
patients with grade 2 or 3, corresponding to
moderate to severe wrinkles at maximum
contraction, were eligible to enroll in the
study. Patients had to be aged 18–65 years to
be included. Patients were excluded if they had
any of the following: pregnancy, treatment with
ABO or ONA in the preceding 9 months, surgery
around the eye, facial scars that would interfere
with assessment of wrinkles, thick sebaceous
skin, dermatochalasis, neuromuscular disorders
such as myasthenia gravis or multiple sclerosis,
use of aminoglycoside or curare-like agents,
history of facial nerve palsy, and psychiatric
illnesses that would interfere with subject
assessment of wrinkles.
Randomization and Masking
Patients were randomized into one of two
groups using a computer-generated
randomization list. The two groups were: (1)
ABO injection on the right side of the face and
ONA on the left; and (2) ONA injection on the
right side of the face and ABO on the left. This
allowed each patient to act as their own control,
thereby limiting variability from patient to
patient (i.e., muscle mass). The physician was
the injector as well as an evaluator. The
physician, second evaluator, and patient were
blinded to the treatment.
Block randomization was prepared in groups
of six. A medical assistant kept the
randomization list and was the only person
who knew which side which treatment was
being given. The patient number and treatment
were determined at baseline visit. Prior to
treatment syringes were placed in the
treatment room with instructions for the area
and side for the treatment to be injected.
Fig. 1 The four-point grading scale used to evaluate wrinkle severity at maximum contraction in the glabellar and crow’s
feet areas: 0 = no wrinkles, 1 = mild wrinkles, 2 = moderate wrinkles, 3 = severe wrinkles [13–15]
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Treatment Regimen
The physician prepared ONA and ABO in
separate 0.3-ml insulin syringes and
reconstituted each with 0.9% preservative-free
saline. ABO was diluted in 3 ml of saline to
make concentrations of 20 U for the glabellar
area and 30 U for the crow’s feet area. ONA was
diluted in 2.5 ml of saline to make a
concentration of 8 U for the glabellar area and
in 3 ml of saline to make a concentration of
10 U for the crow’s feet area. Syringes for the
glabellar area were prepared to a final volume of
0.2 ml and syringes for the crow’s feet area were
prepared to a final volume of 0.3 ml so that
syringes for each area would look identical in
order to make the treatment unknown to the
injector.
The doses were standard for unilateral areas
at 20 U ABO and 8 U ONA for the glabellar area,
and 30 U ABO and 10 U ONA for the crow’s feet
area. Each patient received treatment in the
frown and/or crow’s feet area(s) based on the
degree of wrinkles (moderate to severe). Figure 2
shows the injecting points for the glabellar and
crow’s feet areas. A total of three injecting
points were performed in the glabellar area
unilaterally and all were injected into the
corrugator supercilii muscle. A total of three
injections were given in the unilateral crow’s
feet area: tail of the brow, lateral canthus, and
inferolateral from the lateral canthus. All were
1–1.5 cm from the lateral canthus. Volume in
the syringe was distributed in the three sites of
the glabellar area unilaterally at a percentage
from medial to lateral at 40%/40%/20%, and
evenly distributed in the three sites in the
crow’s feet area.
Study Parameters
The parameters used to compare ONA and ABO
included time to improvement of wrinkles,
improvement in the grading of wrinkles based
on a four-point scale at specific time points,
patient satisfaction, and duration of activity by
complete return of muscle activity. Time to
improvement was also recorded by patients.
Duration of improvement, indicated by
complete return of muscle activity, was
assessed by the evaluator at the follow-up visit.
Response was defined as an improvement of at
least one grade at maximal contraction based
on evaluator assessment. Duration of effect was
defined as the complete return of muscle
activity and was assessed by patients and the
evaluator. Patient satisfaction was recorded by
the subject on a diary card at each follow-up
visit, and was measured based on patients’ own
feeling of improvement in appearance of
wrinkles using a scale from 1 to 5, where
1 = minimally satisfied and 5 = extremely
satisfied.
Safety and efficacy evaluations for wrinkle
severity at maximum contraction were
conducted at the baseline visit, and at follow-
Fig. 2 Unilateral injecting points for the glabellar and
crow’s feet areas
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up visits at 2 weeks, 1 month, 3 months,
4 months and 5 months. Patients were
informed of the possible side effects and were
told to call or return immediately if any of the
following occurred: neck pain, difficulty
swallowing, shortness of breath, nausea,
weakness, double vision, trouble breathing,
talking, or swallowing, hoarse voice, crusting
or drainage from the eyes, severe skin rash or
itching, fast, slow, or uneven heartbeats,
general ill feeling, fever, cough, sore throat,
runny nose, flu symptoms, dry mouth, dry eyes,
increased sweating in areas other than the
underarms, itchy or watery eyes, or increased
sensitivity to light.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2000
and 2008. Informed consent was obtained from
all patients for being included in the study.
Statistical Analysis
Due to the paired nature of the data, the
Wilcoxon signed rank test was used to
compare differences in onset time and
duration of ONA and ABO. The Wilcoxon
signed rank test is a non-parametric version of
a paired samples t test. Analysis was done using
SAS software Version 9.2 of SAS Institute Inc.,
Cary, NC.
The study was Institutional Review Board
approved and was conducted in a private
practice.
RESULTS
Ninety-three patients were treated with ABO
and ONA over a period of 2 months (87 women
and 6 men). Most patients were Caucasian with
an average age of 47 years. Thirty-six patients
received treatment with ONA and ABO in two
areas (glabella and crow’s feet areas). Fifty-seven
patients received treatment with ABO and ONA
in one area (either glabella or crow’s feet areas).
Eight patients did not continue follow-up visits
and were removed from the study, leaving 35
patients treated in 2 areas and 50 patients
treated in 1 area, for a total of 59 patients
treated in the glabellar area and 61 patients
treated in the crow’s feet area. No patients
discontinued visits due to adverse effects from
the treatment.
Time to Onset
All patients had onset of improvement in the
glabellar area within 5 days when using ABO
and ONA, with 28% reporting improvement
within one day with ABO and 17% with ONA,
59% by the second day with ABO vs. 37%
with ONA, 85% by the third day with ABO vs.
70% with ONA, 89% by the fourth day with
ABO vs. 87% with ONA, and 100% by the
fifth day with both treatments (Fig. 3a). Time
to onset was significantly quicker with ABO
than ONA, with a mean difference of
0.52 days (P\0.0001).
In patients injected with ABO in the crow’s
feet area, 19% reported onset by the first day,
54% by the second day, 80% by the third day,
90% by the fourth day, and 100% by the third
day (Fig. 3b). In patients injected with ONA in
the crow’s feet area, 13% responded within the
first day, 39% by the second day, 68% by the
third day, 88% by the fourth day, and 100% by
the fifth day (Fig. 3b). As with the glabellar
region, time to onset was significantly quicker
with ABO than ONA, with a mean difference of
0.33 days (P = 0.0025).
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Duration of Treatment/Response Rate
In the glabellar region, the response rate was
equivalent for ONA and ABO at 2 weeks (100%),
1 month (98%), and 3 months (98%) (Fig. 4a).
The response rate was higher with ABO at
4 months (83% vs. 48% with ONA) and at
5 months (27% vs. 2% with ONA), with
significant mean difference in duration of
2.5 weeks (P\0.0001).
The early response rate in the crow’s feet
region was equivalent for ONA and ABO with
100% of patients responding at 2 weeks and
1 month and a similar rate observed at
3 months (100% with ABO vs. 98% with ONA)
(Fig. 4b). The response rate was higher with
ABO at 4 months (65% vs. 47% with ONA) and
at 5 months (22% vs. 0% with ONA), with
significant mean difference in duration of
1.6 weeks (P\0.0001).
Evaluator Assessment
For patients at 2 weeks, 1 month, and 3 months,
blinded evaluators reported that a greater
proportion of patients had fewer wrinkles on
the side where ABO was injected than the side
with ONA for both the glabellar and crow’s feet
areas (Fig. 5a, b). At 4 months, equal numbers of
patients had less wrinkles on the side with ONA
Fig. 3 Percentage of patients who had onset of action for
ABO and ONA within the ﬁrst day, by the second day,
third day, fourth day, and ﬁfth day in a the glabellar region
and b the crow’s feet region
Fig. 4 Response rate for ABO and ONA at speciﬁc time
points in a the glabellar region and b the crow’s feet region
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vs. ABO and ABO vs. ONA. This was seen for
both the glabellar and crow’s feet areas. In a
large number of patients, no difference was
noted between the two sides at each specific
time point.
Patient Satisfaction
Patient satisfaction showed that a larger
percentage of patients were more satisfied with
ABO than ONA at 2 weeks and 1 month (Fig. 6a,
b). Additionally, there is an increasing rating of
satisfaction from 2 weeks to 1 month with both
ABO and ONA, indicating a peak effect of both
treatments during this time. Five patients gave a
rating of 3, and 8 patients gave a rating of 2 for
ABO in the glabellar region at 5 months
reporting that they felt there was still a slight
effect of ABO at 5 months. Two patients gave a
rating of 3, and 8 patients gave a rating of 2 for
ABO in the crow’s feet area at 5 months
reporting that there was still a slight effect of
ABO at 5 months (Fig. 6b). No patients reported
activity for ONA at 5 months in the glabellar or
crow’s feet region.
Safety
Three patients experienced headaches after
injection, which resolved after a week and
may have been unrelated to the injection. One
Fig. 5 Evaluator assessment for wrinkle severity in a the
glabellar region and b the crow’s feet region. A[O = side
with ABO had less wrinkles than side with ONA.
O[A = side with ONA had less wrinkles than side with
ABO. Same = degree of wrinkles on both sides were the
same
Fig. 6 Patient satisfaction for ABO and ONA using a
rating scale from 1 to 5 at speciﬁc time points in a the
glabellar region and b the crow’s feet region
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patient had slight bruising and this also
resolved within one week. Throughout the
course of the study, one patient developed
brow ptosis with ABO as seen by patient and
evaluator assessment.
DISCUSSION
Differences were observed in the time to onset
of improvement of wrinkles between the two
sides/agents, such that a larger number of
patients had a quicker onset of action with
ABO than with ONA. After 3 months, ABO was
active for a larger percentage/number than
ONA for the glabellar and crow’s feet regions,
although there was an increase in the number
of patients who reported no difference between
the two treatments at this time. Response
rates for ABO and ONA were equivalent in
both regions up to approximately 3 months;
however, the response rates were higher
at 4 and 5 months with ABO. Patient
satisfaction findings were generally consistent
with evaluator assessments at each time
point.
Rapid onset was observed with ONA in a
short-term 14-day study [16]. Beer et al.
evaluated the onset of action of ONA and
found that 48% of patients reported
improvement by day 1, 77% by day 2, 93% by
day 3, 98% by day 4, and 100% thereafter. In
the current study, ABO and ONA were
administered in the glabellar region at a ratio
of 2.5:1 (20 U for ABO vs 8 U for ONA) and in
the crow’s feet region at a ratio of 3:1 (30 U for
ABO vs 10 U for ONA). Three studies by Lowe
et al. compared the efficacy of ABO and ONA for
upper facial lines. In one study, injecting
glabellar lines at doses of ONA (30 U) and
ABO (75 U; 2.5:1 ratio) showed similar efficacy.
In another study, ONA (256 U total) was
significantly more effective than ABO (64 U
total) (dose ratio of 4:1) for upper face lines.
However, an objective measurement by
computerized photographic numerical assessment
showed greater efficacy in the crow’s feet region
with ABO vs ONA when a 3:1 dose ratio (96 U:32 U)
was used [17].
Both ABO and ONA have the same
pharmacology and act by inhibiting the
calcium-mediated release of acetylcholine from
the nerve ending, causing temporary muscle
paralysis. Side effects can occur and range from
mild due to the injection itself or severe due to
the effects of the toxin such as difficulty
swallowing, difficulty breathing, double or
blurred vision, change of voice, or muscle
weakness. The safety profile was similar for
both products with mild adverse events
reported, which resolved within one week.
One (of 85) patients developed brow ptosis on
the side that was injected with ABO. Brow ptosis
is said to develop by diffusion of the toxin into
the frontalis from the corrugator muscle. More
dilute concentration is preferable in order to
increase spread and field of effect (as in the
forehead), whereas lower volumes are preferred
in smaller muscle groups to avoid migration
into unplanned areas [18]. On the other hand,
more concentrated solutions reduce reliability
in delivering a specific unit dose, and more
dilute solutions lead to greater spread of the
toxin [18]. In our study, ABO was given as a
dilution of 300 U in 3 ml for the glabellar and
crow’s feet areas and ONA was reconstituted
with 2.5 ml in a 100 U vial for the glabellar area
and 3 ml for the crow’s feet area. For the
glabellar region, we recommend adjusting the
amount of diluent (1.5–2.5 ml) for both ABO
and ONA to result in a more concentrated
solution in order to decrease the migration of
treatment into the levator and frontalis muscle
and prevent brow ptosis.
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In our study, we sought to achieve the
minimal efficacious dose that would produce
optimal benefits with the lowest risk. At doses of
20 and 30 U ABO for the unilateral glabellar and
unilateral crow’s feet regions, respectively,
onset of action based on patient self-
assessment was shown to be significantly
quicker than with ONA at 8 U in the
unilateral glabellar and 10 U in the crow’s feet
regions. Other studies compared the efficacies
of ABO and ONA in different patients and thus
do not account for variations between
individuals, such as muscle mass and severity
of wrinkles [17]. The current study was an
internally controlled, prospective study with
blinding of the patients as well as the evaluators
and thus established better measures to
compare clinical efficacy (Fig. 7).
We used three injections for the corrugator
unilaterally although in clinical practice, two
injections are used for this muscle. The dose of
ABO recommended by the label (50 U for the
frown on both sides, 10 U per injection point, 5
injection points) gives 20 U for each corrugator,
which is the same dose used in our study. We
spread the dose over three points instead of two
for the purpose of better anatomic treatment of
the corrugator and to have the patient serve as
their own internal control in order to
objectively measure the differences in efficacy
between the two treatments. The findings from
our study, which establishes key parameters
(onset of action, duration of effect, doses, and
side effects) for ABO and ONA, allows the
patient to opt for the more beneficial and
economic product with little risk of adverse
effects, a desirable faster onset with a longer
duration between treatments.
The major limitation of the study was that we
could not inject the glabellar muscle as is done in
practice in order to make comparisons between
the two treatments in the frown region.
CONCLUSION
In conclusion, our experience with ABO
demonstrated a greater duration of activity
and more rapid time to onset in a larger
number of patients in comparison with ONA
when used at a dose ratio of 2.5:1 in the
glabellar region and 3:1 in the crow’s feet
region. The safety profile was similar for both
products. These findings suggest that ABO is a
safe effective alternative to ONA when injected
for treatment of wrinkles in the glabellar and
crow’s feet areas. For the glabellar area, we
recommend more concentrated forms, more
injection areas, and more superficial injections
to decrease the incidence of brow or eyelid
ptosis and to decrease the migration of
treatment.
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